Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, a Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

Precigen ActoBio, announced additional positive interim data from the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics^™ for the treatment of recent-onset type 1 diabetes.